Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
![](/.resources/ModuloCUN/themes/nurun/cysnet/loading.gif)
![](/.resources/ModuloCUN/themes/nurun/cysnet/loading.gif)
![](/.resources/ModuloCUN/themes/nurun/cysnet/loading.gif)
-
July 16, 2024Pamplona/MadridIn recruitment
GO44457 Clinical trial to evaluate the efficacy and safety of neoadjuvant immunotherapy combinations in patients with surgically resectable hepatocellular carcinoma (MORPHEUS-NEO HCC).
The purpose of this study is to compare the effects, good or bad, that AIT (antineoplastic immunotherapy) combinations have on you and your liver cancer, to find out which treatment is best. The AIT combinations are experimental drug treatments, which means that they are not approved by health authorities for the treatment of liver cancer as neoadjuvant therapy (treatment of cancer before surgery). -
July 16, 2024Pamplona/MadridIn recruitmentEarly phase
XB002-101 Clinical trial to evaluate the safety and pharmacokinetics of xb002 in monotherapy and polytherapy in patients with solid tumors.
The objective of this study is to determine the DMT and/or RD to further evaluate the intravenous (i.v.) administration of XB002 in monotherapy and polytherapy in patients with advanced malignancies. -
July 10, 2024PamplonaIn recruitmentEarly phase
IMMUWHY Trial with durvalumab (MEDI4736) odurvalumab and tremelimumab, in patients with advanced stage intrahepatic bile duct cancer (BTC) who were to receive SIRT Y-90 therapy as standard treatment.
The aim of this clinical trial is therefore to combine for the first time two treatment methods (immunotherapy with concomitant SIRT treatment) to test whether in the future it could be useful to treat bile duct carcinoma with immunotherapy and concomitant SIRT treatment. -
July 10, 2024Pamplona/MadridIn recruitmentEarly phase
RMC-6291-101 Clinical trial of RMC-6291 in combination with RMC-6236 in participants with advanced solid tumors with the KRASG12 mutation.
The purpose of this study is to analyze a combination of 2 new drugs called RMC-6291 and RMC-6236 (the study drugs). This study will look at the safety and antitumor effects of RMC-6291 and RMC-6236 when given together at different doses in participants with KRASG12C-mutated solid tumors. It will also analyze how their body processes RMC-6291 and RMC-6236 when they are administered together. -
July 1, 2024MadridIn recruitment
V940-007 Phase 2/3 study of (Neo)adjuvant V940 and pembrolizumab in cSCC
The main objective is to compare V940 plus pembrolizumab with SOC with respect to EFS. -
July 1, 2024Pamplona/MadridIn recruitment
D7230C00001 AZD0305 trial in participants with multiple myeloma.
The purpose of this trial is to learn whether the trial drug will be safe, tolerable and effective in the treatment of patients with multiple myeloma and also to better understand the disease being studied and the associated health problems. -
July 1, 2024Pamplona/MadridIn recruitmentEarly phase
RAD-18-003 Phase II clinical trial in patients with advanced high-grade serous or endometrioid epithelial ovarian, fallopian tube or primary peritoneal cancer who are scheduled for neoadjuvant chemotherapy and cytoreductive surgery.
The objective is to further determine whether Radspherin® can have a positive effect on disease progression in people with ovarian cancer after surgical treatment. This study will also further evaluate the safety of Radspherin®. -
June 13, 2024Pamplona/MadridIn recruitmentEarly phase
GO44479 ENSAYO DE DE CEVUMERAN AUTOGÉNICO MÁS ATEZOLIZUMAB Y mFOLFIRINOX EN COMPARACIÓN CON mFOLFIRINOX EN MONOTERAPIA COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON ADENOCARCINOMA DUCTAL [SP]
The objective of this study is to compare the effects, good or bad, of the combination of autogenic cevumeran plus atezolizumab and FOLFIRINOXm compared to FOLFIRINOXm in monotherapy in patients with resected ADP. In this study, you will receive the combination of autogenic cevumeran plus atezolizumab and FOLFIRINOXm or FOLFIRINOXm in monotherapy.... -
June 13, 2024Pamplona/MadridIn recruitment
MCLA-129-CL01 Clinical trial of MCLA-129 in patients with advanced NSCLC and other solid tumors.
The goal of this study is to find out the possible side effects of the study drug, whether the study drug can stop the growth or spread of cancer cells in your body, how your body processes the study drug, and how certain biomarkers or small substances in your body change in response to the study drug. -
June 13, 2024PamplonaIn recruitmentEarly phase
FS222-19101 Trial to evaluate the safety and antitumor activity of FS222, a bispecific antibody against CD137/PD-L1, in subjects with advanced malignancies.
The aim is to determine whether FS222 is safe in the treatment of cancer and the degree to which a person tolerates the side effects.